On April 7, 2026, Gilead Sciences signed a definitive agreement to acquire Tubulis GmbH, a private, clinical-stage ADC company based in Munich. Terms: $3.15B in upfront cash, plus up to $1.85B in contingent milestone payments. Total consideration up to $5B. Financed with cash on hand and senior unsecured notes and expected to close in Q2 2026.

Tubulis had two clinical assets and a next-generation conjugation platform: TUB-040, a NaPi2b-directed topoisomerase-I inhibitor ADC in Phase 1b/2 for platinum-resistant ovarian cancer and non-small cell lung cancer; TUB-030, a 5T4-targeted ADC in multiple solid tumor indications; and the Tubutecan linker-payload technology and an earlier-stage pipeline.

This was Gilead's third acquisition in roughly six weeks, following Arcellx for $7.8B in February and Ouro Medicines for up to $2.2B in March.

If you take away one thing from this deal, it’s this: Tubulis didn't wake up one morning to find Gilead at the door. Tubulis spent several years running an escalating sequence of partnerships that each served a specific strategic function, with each one de-risking the next.

First was a partnership with BMS. Then Gilead came in through a collaboration. Then Gilead came back with an option-and-license. Then Gilead bought the whole company.

If you're a founder and you think of “partnerships”, “fundraising” and “exit strategy” as separate lanes, and separate problems to be solved, I hope this deal inspires you to widen the aperture.

In fact, I can’t think of a better case study that sums up the path of getting a biotech from the lab to an exit: who & what validates your science, in what order, at what price, and how those validations line up to increase your enterprise value.

Let’s walk through how the Tubulis team pulled this off.

2019: Founded in Munich

Tubulis spun out of two German research institutes. Co-founder and CEO Dominik Schumacher built the company around a conjugation chemistry designed to solve what he calls ADCs' “stability-toxicity paradox” - the problem of payload release before the drug reaches the tumor.

July 2020: Series A led by HTGF

HTGF (High-Tech Gründerfonds), Germany's state-backed early-stage fund, engaged during the pre-founding phase and co-led the €10.7M Series A. Worth noting: HTGF wasn't a name brand VC that most of us have on our lists, at least here in the US. It was the right local anchor for a Munich biotech that needed a patient, deeply-networked investor for the long haul.

April 2023: Bristol Myers Squibb license

BMS paid $22.8M upfront for access to Tubulis' platform, committing over $1 billion in potential milestones to develop ADCs for solid tumors. This was the first major breakthrough moment for Tubulis. A top-tier pharma had publicly validated the chemistry - not just a single molecule, but the underlying platform. Just as importantly, the deal opened up a non-dilutive capital channel. The upfront and milestone payments could be reinvested directly into R&D and platform expansion without forcing another venture round, letting Tubulis grow the company on the back of pharma money rather than founder dilution.

March 2024: Series B2 of €128M ($138.8M)

The round was co-led by EQT Life Sciences and Nextech Invest, with US-based Frazier Life Sciences and Deep Track Capital joining the syndicate alongside all existing investors . The round was upsized and oversubscribed. Capital was earmarked for three things: clinical entry for both lead candidates (TUB-040 in NaPi2b-positive ovarian and lung cancer, TUB-030 in 5T4-expressing solid tumors), continued platform expansion for future payloads and conjugation chemistries, and establishing a US subsidiary to support American investor and clinical relationships. This was the moment Tubulis went global. The BMS license generated data and validation that anchored the B2 raise, which in turn funded the clinical execution that made the next pharma partnership possible - a pattern that would repeat across the next two years.

June 2024: FDA Fast Track for TUB-040

The regulatory stamp came on the lead asset targeting NaPi2b. Fast Track itself doesn't lower the approval bar, but it does compress review timelines through Rolling Review (FDA reviews completed sections of the BLA as they're submitted, rather than waiting for the full package) and opens eligibility for Priority Review and Accelerated Approval if criteria are met. For Tubulis, the more important effect was as the next link in the validation chain: a regulatory “yes” that added agency-side confidence to a story that already had pharma and venture validation behind it.

December 2024: Gilead exclusive option-and-license

Gilead paid $20M upfront, with a $30M option exercise fee if exercised, and committed 415M in development and commercialization milestones, plus tiered royalties. The collaboration: Tubulis leads early-stage discovery and development of a new Topo-I-inhibitor-based ADC against an undisclosed solid tumor target, using Tubulis' Tubutecan and Alco5 platforms; if Gilead exercises its option, it takes over development and commercialization. The crucial word here is exclusive - not for the whole Tubulis platform, but for the new ADC program they were co-designing against this specific target. Tubulis kept the platform free for their own clinical programs (TUB-040, TUB-030) and for future deals against other targets. What Gilead bought wasn't access to the lead asset. It was a structured 18+ month window to watch Tubulis execute on a new program. For Gilead, this was a much cheaper way to assess platform quality than buying the company outright. Exclusivity at this stage is rarely the buyer's casual preference. It's how pharmas pre-position acquisitions 18-24 months before they're ready to commit publicly.

October 2025: ESMO data drop

Tubulis presented late-breaking, first-in-human, oral data on TUB-040 in platinum-resistant high-grade serous ovarian cancer at ESMO 2025. The data was as strong as you could wish for a Phase 1/2a interim readout. But more importantly, this was the first clinical readout where a NaPi2b-targeted ADC actually worked - Mersana, Roche, and Zymeworks had all previously failed at the same target. This made TUB-040's data a category-validation moment, not just an asset-validation one. This is what gave Tubulis the leverage to close its Series C weeks later, and what made Gilead's eventual acquisition feel less like a leap of faith and more like a foregone conclusion.

Late October 2025: Series C closes at €344M ($401M), led by Venrock

Other investors included Fidelity, Janus Henderson, and Blackstone. The round was the largest Series C ever for a European biotech and the largest private ADC financing globally. The previous Series B2 had done its job: the US subsidiary, the clinical execution, and the ESMO readout together let Tubulis run this round from a position of strength, bringing in tier-one US crossover and public-market investors who weren't even in the syndicate eighteen months earlier.

April 7, 2026: Gilead acquires for up to $5B

HTGF calls this their highest-valued exit to date and the third unicorn exit in their life sciences portfolio.

Six and a half years from founding. Three financing rounds totaling over $500M of institutional venture. Two pharma partnerships. One category-defining readout.

Then the exit.

Put like that, this can sound predetermined. Or like a one-in-a-million outcome with nothing to teach the rest of us. Neither is true - and I hope that seeing the steps in detail can make the difference.

Now, let's look under the hood at how Gilead structured this deal.

Most founders read “$3.15B upfront, $1.85B milestones” and move on - don't. There is a lot here to unpack.

Gilead paid 63% of the total deal upfront - $3.15B of the $5B. For context: in a typical pharma-biotech licensing deal, upfront payments average roughly 6-7% of announced deal value. This trend has only increased in 2025-2026, with milestone-driven structures becoming the norm for de-risking buyer commitment. Gilead deciding to put more than 60% of the value upfront for a company still in Phase 1b/2 cuts directly against that trend.

So why structure the deal this way? Was Gilead just splashing the pot? 🙂

A few hypotheses:

The most likely answer is some combination of the first three, with the fourth providing the underlying confidence to act. My guess: Gilead already had one foot in the door through the 2024 option. Letting Tubulis walk away to a rival, to an IPO, or to fall apart entirely - was a risk Gilead couldn't afford to take. And if Tubulis IPO'd and successfully scaled the platform, buying them back in just a few years would have cost 10-15x more.

The deal was done with cash on hand plus senior unsecured notes and no stock component. This is interesting, because biotech M&A often uses stock or a hybrid. The Anthropic-Coefficient Bio deal, for example, was all stock. The Gilead-Tubulis deal was the opposite: cash at closing, debt to fund the rest, no Gilead shares changing hands.

Here are the potential implications for both parties:

Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation. This is the “Kite Pharma model,” named after Gilead's 2017 cell therapy acquisition, which it has kept structurally separate to preserve scientific culture. Gilead is not absorbing Tubulis. They're acquiring the platform, the team, and the facilities, and leaving the scientific operation intact in Munich. For founders, this matters: how you negotiate the post-close integration structure is part of the deal, not an afterthought.

The $1.85B in contingent milestones is unspecified in the public announcement. But based on typical deal architecture in oncology transactions, these are most likely tied to: (1) Phase 3 initiation for TUB-040, (2) FDA approval in platinum-resistant ovarian cancer, (3) label expansion into NSCLC, and (4) sales thresholds. That structure aligns Tubulis' continuing employees, and the venture investors holding escrow, with Gilead's execution team.

What this deal tells us about the state of pharma in 2026.

Daiichi Sankyo, AstraZeneca, Pfizer, and now Gilead are all investing heavily in next-generation conjugation and payload technologies. Every Big Pharma with a patent cliff problem and an oncology franchise is now competing for ADC platform ownership. IQVIA estimates $230B of biopharma industry revenue will face loss-of-exclusivity exposure by 2030, with blockbusters like Keytruda, Gardasil, Eliquis, Jardiance, Opdivo, Darzalex, and Cosentyx losing exclusivity by the end of the decade.

The harder truth: oncology is one of the few therapeutic areas that can absorb that revenue replacement at scale, and within oncology, most novel modalities (cell therapy, bispecifics, cancer vaccines) are still 5-10 years from peak commercial deployment. ADCs are one of the rare categories that combine clinical validation, near-term commercial potential, and platform leverage - which is why the same 6-8 pharma giants are all bidding on the same finite pool of platform companies.

Gilead's three acquisitions in six weeks (Arcellx, Ouro, Tubulis) aren't isolated opportunism. They're a response to a structural pressure that every other Big Pharma is feeling. The deals will keep coming.

For founders building in ADCs or related modalities (degrader-antibody conjugates, radio-conjugates, next-gen payloads), the dynamic right now has the potential to be, I dare say, hopeful: multiple serious strategic buyers are actively shopping for platforms, each racing the others to avoid being the last to buy. If you're approaching the clinic with differentiated chemistry, this is the rare moment where being the seller, not the buyer, may put you in a structurally advantaged position.

Read the major oncology M&A deals of the last decade and you'll see a pattern shift. The 2016-2022 wave was asset-driven: pharmas paid premium prices to acquire single approved or near-approved oncology molecules with proven commercial traction. Pfizer bought Medivation for $14B in 2016 to acquire Xtandi, an androgen receptor inhibitor already generating $2.2B in annual sales. Gilead bought Immunomedics for $21B in 2020 to acquire Trodelvy, a single ADC with a single approved indication. AstraZeneca and Daiichi Sankyo's Enhertu collaboration followed similar logic. The bet in each case was the same: own the molecule, capture the commercial value.

Trodelvy, per STAT, hasn't yet become the kind of seller Gilead once envisioned. The single-asset thesis doesn't compound. Once the molecule plateaus, the franchise plateaus.
The 2023–2026 wave is platform-driven. Gilead paid $3.15B upfront for a Phase 1b/2 company with no commercial product because they're not buying TUB-040. They're buying the chemistry, the team, and the ability to make the next ten ADCs against the next ten targets. The platform is the asset.

This shift matters even if you're not in ADCs. Pharma's preference for platform acquisitions over single-asset acquisitions is now visible across modalities - cell therapy, T-cell engagers, gene editing, RNA medicines. Position your company accordingly. Whether you have a platform, a hero molecule, or something in between, the pitch you build needs to articulate what your science unlocks beyond the lead asset. That framing is what allows you to negotiate and grow from a position of strength.

There's a persistent narrative that European biotechs have to relocate to Boston or SF to get serious venture capital and serious strategic buyer attention. The Tubulis story flies in the face of that narrative.

They stayed in Munich. They raised a monumental Series C. They got acquired by a top-tier US pharma for up to $5B. The Munich site is specifically named as the future hub for Gilead's ADC innovation, meaning the exit didn't trigger relocation. Quite the opposite.

For European founders reading this: the path no longer has to be “Boston or bust.” Instead, the question becomes: “are we close enough to at least one of our validating partners that the relationship has depth?” Tubulis opened an office at the Cambridge Innovation Center not to fully relocate, but to have a presence with US investors and clinical collaborators. So, it seems you can have your cake and eat it too: keep the scientific center in Europe, establish a US beachhead for relationship capital.

Now that you have the full story, here are three lessons that you can apply to your own journey today.

Every pharma partnership you sign is, whether you frame it this way or not, a years-long audition for acquisition. The BMS 2023 deal validated Tubulis' platform. The Gilead 2024 option gave Gilead 18 months of “inside the tent” access before committing to the full buy. By the time Gilead signed the $5B acquisition in 2026, they had already watched the team run a clinical program, hit regulatory milestones, and execute on platform expansion for more than two years. The acquisition was a natural continuation of the relationship.

What to do: When you structure your first pharma collaboration, design it as the front end of an optionality pathway. Collaboration → option → acquisition is a real, negotiable progression, and the terms of the first stage affect your leverage at every subsequent step. Don't let your BD lawyer draft a “standard” collab agreement. Draft with your eye towards further agreements that may be years in the making.

Gilead paid $3.15B upfront for a Phase 1b/2 company with no commercial product. That valuation only makes sense if you're paying for what TUB-040's data unlocks - validation of the underlying conjugation chemistry, which opens up ovarian, NSCLC, and an expanding pipeline of solid tumors.

Most founders get this backwards. They treat winning the indication as the destination. But each indication is a vehicle for validating something deeper - the platform, the mechanism, the modality, the target class. Ovarian cancer wasn't Tubulis' goal. It was the first proof point that their chemistry could deliver therapeutic windows other ADC platforms couldn't. This validates whether you're a platform company or a single-asset company.

The deeper game underneath is the flywheel: capital funds trials, trials produce data, data validates the underlying technology in indication #1, and that validation unlocks both follow-on indications and more capital. More capital, more trials, more data, more indications, more capital. This is exactly the flywheel that Tubulis executed: Series A funded the platform. The platform attracted BMS. BMS validation raised more capital and attracted Gilead. Gilead's option deal funded clinical execution. ESMO 2025 data unlocked the largest European biotech Series C in history. That capital expanded the pipeline. The expanded pipeline justified the $5B exit.

What to do: Audit your pipeline strategy. For each indication on your roadmap, ask: what does success here validate beyond the indication itself?

The first major partnership Tubulis signed was with BMS in 2023, not Gilead. That deal became the social proof that made Gilead's 2024 option economically and reputationally easier to justify. FDA Fast Track added regulatory validation. ESMO 2025 added clinical validation. The Venrock-led Series C added financial validation. By April 2026, every major stakeholder in biotech had already endorsed the story.

Most founders think about validators within a single category - get more capital, then more capital, then more capital. Or chase one regulatory milestone, then the next, then the next. Tubulis stacked them across categories. The BMS deal (commercial validator) made the FDA Fast Track filing more credible. The FDA designation (regulatory validator) made the Series B2 raise easier. The Series B2 (capital validator) funded the clinical execution that produced ESMO data (clinical validator), which in turn unlocked the Series C. Each “yes” in one category lowered the bar for the next “yes” in a different category. That cross-category compounding is the true superpower.

What to do: Build a 36-month validator calendar across all four categories - commercial (pharma deals), regulatory (FDA designations), clinical (data readouts and KOL endorsements), and capital (investor rounds). Which pharma “yes” do you target first? Which regulator milestone? Which KOL or congress slot? Which lead investor? Each “yes” de-risks the next one across categories, not just within them. And as you get further into dealmaking territory, maintain a live list of which pharmas are in buying mode, organized by active modality gaps. Update this after every JPM, every earnings call, every major announcement.

We made it! Now we can take a deep breath 🙂

Was this teardown helpful? Should I do more of these in the future? This is still a bit of an experiment, so I’d love your feedback.

You can vote through the poll below or just reply to this email, I’d love to hear from you.

See you next Sunday!

- Vadim

PS: Are you working through pharma BD or fundraising right now and want to talk through it? Reply to this email and let me know!

PPS: Know someone who'd benefit from this? Forward it their way and tell them to subscribe at biofounder.io